Vancouver, Jan. 17, 2024 (GLOBE NEWSWIRE) -- The global Intravenous Immunoglobulin (IVIG) market size was USD 12.10 Billion in 2022 and is expected to register a revenue CAGR of 7.5% during the forecast period. Increasing prevalence of immunodeficiency disease, rising adoption of Intravenous immunoglobulin treatment and rapid technological advancement in therapy are key factors driving market revenue growth. In addition, growing investment in healthcare industry is contributing significantly to the market growth. The intravenous immunoglobulin market has grown rapidly, driven by the goal of treating and preventing a wide range of immune disorders. immunoglobulin is a type of protein that is found in the blood.
One of the major factors driving revenue growth of the market is increasing prevalence of immunodeficiency disorders. There are two types of immunodeficiency disease such as primary immunodeficiency and secondary immunodeficiency. The most prevalent secondary immunodeficiency is the one caused by HIV and causes the acquired immunodeficiency syndrome, which prevalence varies globally. World Health Organization (WHO) estimated there are 39 million Individuals living with HIV, 1.3 million individuals acquiring HIV and 630,000 individuals, 84000 children died of HIV related cause. There 20 million women,17.4 million men and 1.5 million children living with HIV. While the prevalence of immunodeficiency disease varies by age and diagnosis, people of all ages everywhere around the world are affected.
A key market trend which is expected to boost revenue growth of this market is rapid technological advancements in therapy. A number of new technologies are developing to be included in immunoglobulin market including Nanoparticle-based IVIG, genetically engineered IVIG, IVIG with reduced viscosity, Plant-derived IVIG, VIG with antimicrobial properties enabling the development of more targeted, personalized, and effective treatments.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-sample/2728
Leading companies are also launching products, which is contributing significantly to revenue growth of this market. For instance, on 14 November 2022, Biotest Ag announced approval for new intravenous immunoglobulin Yimmugo (IgG Next Generation). The sugar-free ready-to-use solution is approved for replacement therapy in primary antibody deficiency syndromes and secondary immune deficiency, as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki’s disease. This product showcases Biotest Ag dedication to provide immune deficiency disease patients with innovative solutions that enable them to achieve the highest standards of patient care without the need for additional instrumentation.
One of the significant challenges hindering revenue growth of the IVIG market is the high cost of therapy. Despite an increasing number of people with immunodeficiency diseases such as HIV, autoimmune diseases, and infectious diseases, the high cost of IVIG therapy limits its use. This is especially applicable in low- and middle-income countries, where reimbursement policies for IVIG therapy are often limited. Rising demand for IVIG therapy and a captive market have allowed drug manufacturers to consistently raise prices, placing a significant financial burden on individuals and healthcare systems. These factors are restraining revenue growth of the global IVIG market.
Segment Insights
Type Insights:
On the basis of type, Intravenous Immunoglobulin (IVIG) market is segmented into IgA, IgM, IgG, IgE, IgD. Among these, the IgG type segment accounted for largest revenue share in 2022. IgG is a type of antibody, as well as a protein that the body produces to fight off infection. IgG is used for an effective treatment for some autoimmune and inflammatory diseases. According to National Stem Cell foundation, there are nearly 4% of the world’s population is affected by one of more than 80 different autoimmune diseases, the most common of which include type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, Crohn’s disease, psoriasis.
Route of administration Insights:
On the basis of route of administration, the global intravenous immunoglobulin market is segmented into intravenous and subcutaneous. Intravenous segment accounted for the largest revenue share in the global intravenous immunoglobulin market in 2022. IVIG administered intravenously exhibits high bioavailability, meaning that a significant portion of the administered antibodies are absorbed into the bloodstream and reach the target sites. This ensures that patients receive the intended therapeutic dose, maximizing treatment efficacy. This further reinforces the dominance of the IV route in the IVIG market. This administration has demonstrated superior efficacy in treating various severe and life-threatening conditions, including Kawasaki disease, primary immune deficiencies, and autoimmune neuropathies.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/2728
Regional Insights:
North America accounted for a relatively larger revenue share than other regional markets in the global intravenous immunoglobulin market in 2022. Increasing prevalence of immunodeficiency diseases is major factor driving revenue growth of the market in this region. According to Center for Disease Control (CDC) and prevention the rate of new HIV infections in the United States was 11.5 per 100,000 Individuals in 2021. In that year, 36,136 Individuals received an HIV diagnosis in the United States. In addition, growing key strategic initiatives as well as partnerships between major market companies is developing revenue growth of the intravenous immunoglobulin market in this region.
Europe accounted for significantly large revenue share in 2022. Increasing prevalence of auto immune illness and primary immunodeficiency disease are key factors driving revenue growth of the market in this region. According to the European center for disease control and prevention, there are more than 2.3 million individuals affected by HIV and nearly 107 000 people were diagnosed with HIV in the European region in 2022, including around 17 000 in the EU and eastern Europe. From this scenario the demand for intravenous immunoglobulin market is expected to rise more as individuals seek advanced and personalized Immunoglobulin therapy options.
Scope of Research
| Report Details | Outcome |
| Market size in 2022 | USD 12.10 Billion |
| CAGR (2023–2032) | 7.5% |
| Revenue forecast to 2032 | USD 24.76 Billion |
| Base year for estimation | 2022 |
| Historical data | 2021-2022 |
| Forecast period | 2023–2032 |
| Quantitative units | Revenue in USD Million and CAGR in % from 2023 to 2032 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Type, Application, Route of Administration, End-Use, and Region |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope | U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA |
| Key companies profiled | Baxter, Pfizer Inc., Johnson and Johnson Private limited, Takeda Pharmaceutical company Limited, Grifols,S.A, CSL, Biotest AG, Octapharma, Bio Products Laboratory Limited, LFB |
| Customization scope | 10 hours of free customization and expert consultation |
Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/2728
Major Companies and Competitive Landscape
The global intravenous immunoglobulin market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective intravenous immunoglobulin market.
Some major players included in the global intravenous immunoglobulin market report are:
- Baxter
- Pfizer Inc.
- Johnson and Johnson Private limited
- Takeda Pharmaceutical company Limited
- Grifols,S.A
- CSL
- Biotest AG
- Octapharma
- Bio Products Laboratory Limited
- LFB
Strategic Development
- On 18 April 2023, CSL Behring announced approval of U.S. Food and Drug Administration (FDA) approved prefilled syringe for Hizentra. The prefilled syringes are for individuals living with living with Primary Immunodeficiency (PI) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This Immune Globulin (Ig) is available in a simple, convenient and ready-to-use prefilled syringe. This announcement reinforces CSL Behring commitment to providing patients by eliminating the need for hospital-administered infusion with their new prefilled syringes. and treatment in the field of immunodeficiency disease.
- On 25 September 2023, Biogen announced LEQMBI Antibody. LEQEMBI is a humanized Immunoglobulin Gamma 1(IgG1) monoclonal antibody provides initial treatment of patients with Alzheimer’s and represents another high-value product for our growing in immunodeficiency disease treatment. This announcement adds Biogen line-up of eliminating the need for the need for hospital-administered infusions, empowering patients to self-administer their medication from the comfort of their own homes.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/intravenous-immunoglobulin-market
For the purpose of this report, Emergen Research has segmented the global intravenous immunoglobulin market on the basis of type, application, route of administration, end-use, and region:
- Type Outlook (Revenue, USD Billion; 2019-2032)
- IgA
- IgM
- IgD
- IgE
- IgG
- Route of administration (Revenue, USD Billion; 2019-2032)
- Intravenous
- Subcutaneous
- Application Outlook (Revenue, USD Billion; 2019-2032)
- Primary Immunodeficiency Diseases
- Myasthenia Gravis
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Hypogammaglobulinemia
- Multifocal motor neuropathy
- Kawasaki Disease
- Guillain-barre Syndrome
- Others
- End-Use Outlook (Revenue, USD Billion; 2019-2032)
- Hospitals
- Clinics
- Homecare
- Regional Outlook (Revenue, USD Billion; 2019-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
Emergen Research is Offering Exclusive Customization as per your Specific Requirements@ https://www.emergenresearch.com/request-for-customization/2728
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights
